

Colorectal Cancer Screening (COL-E)

Description of Measure

Percentage of patients 45 – 75 years of age as of Dec. 31, measurement year (MY), who had appropriate screening for colorectal cancer: colonoscopy, CT colonography, flexible sigmoidoscopy, FIT-DNA, or fecal occult blood test (FOBT).¹

Documentation

Screening Test	Frequency
Fecal Occult Blood (FOBT)	Annually
Cologuard/ FIT-DNA	Every three years, 2 years prior through MY
Flexible Sigmoidoscopy	Every five years, 4 years prior through MY
CT Colonography	Every five years, 4 years prior through MY
Colonoscopy	Every ten years, 9 years prior through MY

- Member reported must state specific colon cancer screening and date.
- Member report colon cancer screenings are acceptable when reported to a primary care provider or a specialist, if the specialist is providing a primary care service related to the condition being assessed, while taking a patient's history.
- Notation of a completed specified colon cancer screening with DOS as part of the medical history. Health maintenance and preventive care sections are considered "history" sections.
- A letter/correspondence must document a specific colon cancer screening test with a completion date of "done today/today" within the body of the letter to meet COL criteria.
- A pathology report that indicates the type of screening and the date meets criteria.
- Member refusal will **not** make them ineligible for this measure.
- Digital rectal exams (DRE) or FOBT test performed in the office setting will **not** meet compliance.

Test Type	Unknown	Guaiac (gFOBT)	FIT (iFOBT)	Unknown
Samples Returned	Unknown or 3 or >	Documented 3 or >	Any # or unknown	Documented 1 -2
Status	Compliant	Compliant	Compliant	Unacceptable Non-compliant



Arkansas
BlueCross BlueShield

An Independent Licensee of the Blue Cross and Blue Shield Association

Exclusions

Exclusions	Time limit								
<ul style="list-style-type: none"> Members who elect or use hospice services Member deceased Members receiving palliative care 	Any time during measurement year (MY)								
<ul style="list-style-type: none"> Colorectal cancer Total colectomy 	Anytime in member's history through Dec. 31 MY								
<p>Members 66 years of age and older by Dec. 31 MY with Advanced Illness and Frailty.</p> <p>Members must meet BOTH frailty and advanced illness criteria to be excluded.</p>	<ul style="list-style-type: none"> Frailty diagnosis on 2 different DOS during the MY Advanced Illness: Either of the following during the MY or PY <ul style="list-style-type: none"> Advanced illness diagnosis on 2 different DOS Dispensed a dementia medication <table border="1"> <thead> <tr> <th>Dementia Med Description</th><th>Prescription</th></tr> </thead> <tbody> <tr> <td>Cholinesterase inhibitors</td><td> <ul style="list-style-type: none"> Donepezil Galantamine Rivastigmine </td></tr> <tr> <td>Misc. CNS Agents</td><td> <ul style="list-style-type: none"> Memantine </td></tr> <tr> <td>Combinations</td><td> <ul style="list-style-type: none"> Donepezil-memantine </td></tr> </tbody> </table>	Dementia Med Description	Prescription	Cholinesterase inhibitors	<ul style="list-style-type: none"> Donepezil Galantamine Rivastigmine 	Misc. CNS Agents	<ul style="list-style-type: none"> Memantine 	Combinations	<ul style="list-style-type: none"> Donepezil-memantine
Dementia Med Description	Prescription								
Cholinesterase inhibitors	<ul style="list-style-type: none"> Donepezil Galantamine Rivastigmine 								
Misc. CNS Agents	<ul style="list-style-type: none"> Memantine 								
Combinations	<ul style="list-style-type: none"> Donepezil-memantine 								

Exclusion Codes

CPTII Code	Definition
Z85.038	Personal history of other malignant neoplasm of large intestine
Z85.048	Personal history of other malignant neoplasm of rectum, rectosigmoid junction, and anus
C18.0-9, C19-20, C21.2, C21.8, C78.5	Colorectal cancer, active

Strategies for Success	<ul style="list-style-type: none"> If a patient has family history of colon cancer, encourage a colonoscopy instead of a Cologuard. Use the Annual Wellness visit to schedule screenings. Add screenings to annual assessment form/ EMR template. Implement a referral tracking process. For patients refusing colonoscopy, recommend a FIT-DNA or FOBT kit. Educate patients on preparation for the ordered tests.

Resources

I. National Committee for Quality Assurance, HEDIS® Measurement Year 2025 Volume 2 Technical Specifications for Health Plans

Arkansas Blue Cross and Blue Shield is an Independent Licensee of the Blue Cross and Blue Shield Association.
© 2023 Arkansas Blue Cross and Blue Shield. All rights reserved.